Cascadian Therapeutics

The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Seattle, US
Size (employees)
57 (est)+8%
Cascadian Therapeutics is headquartered in Seattle, US

Cascadian Therapeutics Office Locations

Cascadian Therapeutics has office in Seattle
Seattle, US

Cascadian Therapeutics Metrics

Cascadian Therapeutics Summary

Market capitalization

$189.5 m

Closing share price

Cascadian Therapeutics's current market capitalization is $189.5 m.

Cascadian Therapeutics Market Value History

Cascadian Therapeutics Company Life

You may also be interested in